Yale University School of Medicine
New Haven, Connecticut, 06510, United States
NCT Number: NCT00622596
The purpose of this study was to expand access to buprenorphine using a mobile health care system among marginalized populations with or at high risk for HIV and observe longitudinal effects of treatment.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
New Haven, Connecticut, 06510, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
Time frame: 10/1/03-9/30/08
To assess the feasibility and efficacy of the use of buprenorphine to treat opioid dependence in high risk populations accessing a mobile health care system using tracked attendance.
Time frame: 10/1/03-9/30/08
To assess the feasibility and efficacy of the use of buprenorphine to treat opioid dependence in high risk populations accessing a mobile health care system using incidence of opioid free urine toxicology.
Time frame: 10/1/03-9/30/08
Yale University
Other
Acronym: Project BEST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03718065
Chemically-Induced Disorders, Mental Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT03527485
Chemically-Induced Disorders, Cocaine Dependence
New Haven, Connecticut, United States
View Trial DetailsNCT03769025
Chemically-Induced Disorders, Mental Disorders
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT04156802
Back Pain, Chemically-Induced Disorders
Winston-Salem, North Carolina, United States
View Trial Details